GSK – ViiV Abandons Lersivirine – An Investigational NNRTI HIV Medication
Dear HIV Community Writer, ViiV Healthcare has taken the decision to stop the development program investigating the non-nucleoside reverse transcriptase inhibitor (NNRTI), lersivirine. This is not due to any safety concerns regarding the compound. ViiV Healthcare’s goal is to support the best possible outcomes for people living with HIV, and to deliver new therapies that …
GSK – ViiV Abandons Lersivirine – An Investigational NNRTI HIV Medication Read More »